<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0015">
 <element-citation publication-type="journal" id="sbref0015">
  <person-group person-group-type="author">
   <name>
    <surname>Luna</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Alping</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Burman</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Fink</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Fogdell-Hahn</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Gunnarsson</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Hillert</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Langer-Gould</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Lycke</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Nilsson</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Salzer</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Svenningsson</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Vrethem</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Olsson</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Piehl</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Frisell</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies</article-title>
  <source>JAMA Neurol.</source>
  <year>2019</year>
  <pub-id pub-id-type="doi">10.1001/jamaneurol.2019.3365</pub-id>
  <comment>https://doi.org/</comment>
 </element-citation>
</ref>
